More than 10,000 cancer researchers, clinicians and patient advocates from across the globe are expected to attend this year’s San Antonio Breast Cancer Symposium. The meeting will feature presentations by several UNC faculty members and trainees.
Nine UNC Lineberger members wrote some of the most influential scientific papers in the past decade, according to an independent analysis of research publications.
In a Journal of Clinical Oncology editorial, Yara Abdou, MD, and Norman E. Sharpless, MD, share their concerns about a growing reliance on industry-sponsored cancer clinical trials in the U.S.
UNC Lineberger’s Center for Triple Negative Breast Cancer held its second annual scientific retreat, bringing together faculty, staff, trainees, patient advocates and cancer center leaders.
Susan G. Komen® has awarded Melissa Troester, PhD, MPH, a two-year, $200,000 leadership grant to support her investigations of the clinical impact of spatial heterogeneity in a tumor.
UNC Lineberger Director Shelley Earp, MD, has been appointed chair of the NCI Board of Scientific Advisors. The board advises the NCI director and program leaders on research priorities.
UNC and UNC Lineberger researchers and trainees will be presenting talks and participating in scientific and educational panels and discussions on the latest cancer research at the ASCO Annual Meeting.
Lisa Carey, MD, ScM, FASCO, was honored for her distinguished service over the years leading outstanding clinical and translational research and her work in eradicating health disparities.
Researchers and trainees from UNC and UNC Lineberger at will present more than 30 talks and participate in scientific and educational panels and discussions on the latest cancer research.
A team of UNC researchers investigated how cell cycle flexibility allows tumor cells to escape the effect of anti-cancer drugs that target cell division.
Missy Van Lokeren was diagnosed with metastatic breast cancer in 2018, and has became a patient advocate spreading awareness for tissue donation through the Patients And Researchers Together (PART) program.
New findings from Gaorav Gupta, MD, PhD, and colleagues show how the cGAS-STING pathway is unleashed to prevent cancer formation by detecting DNA damage within cells.